46-60 of 916
Examining Barriers to Digital Healthcare in PAH
Clinician's RoundtableExamining Barriers to Digital Healthcare in PAH
Daniel Lachant, D.O.
Advances in Sports Cardiology: Updates from ACC 2026
Heart MattersAdvances in Sports Cardiology: Updates from ACC 2026
Jeffrey Hsu, MD, PhD
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
CardiologyEvolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Nicholas Marston, MD
Protecting Heart Health in Metastatic Breast Cancer
On the Frontlines of Metastatic Breast CancerProtecting Heart Health in Metastatic Breast Cancer
Ryan Quigley
Gregory Vidal, MD, PhD
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
Heart MattersSupporting Patients With ATTR-CM: Preserving Function and Quality of Life
Joban Vaishnav, MD
Counseling Patients on Disease Progression in ATTR-CM
Heart MattersCounseling Patients on Disease Progression in ATTR-CM
Joban Vaishnav, MD
- advertisement
Rethinking Thromboembolic Risk in ATTR-CM Care
Heart MattersRethinking Thromboembolic Risk in ATTR-CM Care
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Heart MattersSilencers and Stabilizers in ATTR-CM: Challenging Assumptions
Trends and Disparities in COPD with Secondary Pulmonary Hypertension
Clinician's RoundtableTrends and Disparities in COPD with Secondary Pulmonary Hypertension
Nasibul Alam, MD
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Clinician's RoundtableReframing Palliative Care in PAH: Early Integration to Improve Outcomes
Targeting Macrophages in Pulmonary Arterial Hypertension
Clinician's RoundtableTargeting Macrophages in Pulmonary Arterial Hypertension
Fatty Acid Profiles May Be Linked to PAH Risk
AudioAbstractsFatty Acid Profiles May Be Linked to PAH Risk
Ryan Quigley
- advertisement
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
CardiologySCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
